{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:51Z","timestamp":1791235131410,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s41669-023-00399-x","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:02:40Z","timestamp":1678554160000},"page":"359-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-0152","authenticated-orcid":false,"given":"Tiziana","family":"Magni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pelizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Perez-Kempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Turkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothsna","family":"Nathani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Orlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Meshchenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"399_CR1","doi-asserted-by":"crossref","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","DOI":"10.7326\/M22-1460"},{"issue":"1","key":"399_CR2","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1038\/s41598-020-60091-6","volume":"10","author":"C Course","year":"2020","unstructured":"Course C, Chakraborty M. Management of respiratory distress syndrome in preterm infants in Wales: a full audit cycle of a quality improvement project. Sci Rep. 2020;10(1):3536.","journal-title":"Sci Rep"},{"issue":"2","key":"399_CR3","first-page":"117","volume":"24","author":"K Sekar","year":"2019","unstructured":"Sekar K, Fuentes D, Krukas-Hampel MR, et al. Health economics and outcomes of surfactant treatments for respiratory distress syndrome among preterm infants in US level III\/IV Neonatal Intensive Care Units. J Pediatr Pharmacol Ther. 2019;24(2):117\u201327.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"11","key":"399_CR4","first-page":"994","volume":"92","author":"CL Hermansen","year":"2015","unstructured":"Hermansen CL, Mahajan A. Newborn respiratory distress. Am Fam Physician. 2015;92(11):994\u20131002.","journal-title":"Am Fam Physician"},{"issue":"11","key":"399_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/14767058.2016.1210597","volume":"30","author":"V Condo","year":"2017","unstructured":"Condo V, Cipriani S, Colnaghi M, et al. Neonatal respiratory distress syndrome: are risk factors the same in preterm and term infants? J Matern Fetal Neonatal Med. 2017;30(11):1267\u201372.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"399_CR6","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Garc\u00eda M, Santiago-Guti\u00e9rrez C, Mart\u00ednez-Padilla MC, et al. Survival and factors predicting mortality in preterms infants. J Perinat Med. 2015;43:P-0549. https:\/\/doi.org\/10.1515\/jpm-2015-2003.","DOI":"10.1515\/jpm-2015-2003"},{"issue":"4","key":"399_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000499361","volume":"115","author":"DG Sweet","year":"2019","unstructured":"Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome\u20142019 update. Neonatology. 2019;115(4):432\u201350.","journal-title":"Neonatology"},{"key":"399_CR8","doi-asserted-by":"crossref","unstructured":"Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2016;(6):Cd001243.","DOI":"10.1002\/14651858.CD001243.pub3"},{"key":"399_CR9","doi-asserted-by":"crossref","unstructured":"Polin RA, Carlo WA, Committee on Fetus and Newborn, et al. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014;133(1):156\u201363.","DOI":"10.1542\/peds.2013-3443"},{"key":"399_CR10","unstructured":"National Health Service. Surfactant replacement therapy for neonates with respiratory distress. https:\/\/www.eoeneonatalpccsicnetwork.nhs.uk\/wp-content\/uploads\/2022\/02\/Surfactant-administration_ODN_v2_150418.pdf. Accessed 15 July 2022."},{"issue":"1\u20132","key":"399_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/pr.2016.203","volume":"81","author":"S Sardesai","year":"2017","unstructured":"Sardesai S, Biniwale M, Wertheimer F, et al. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res. 2017;81(1\u20132):240\u20138.","journal-title":"Pediatr Res"},{"issue":"2","key":"399_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1542\/peds.2007-3283","volume":"121","author":"WA Engle","year":"2008","unstructured":"Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419\u201332.","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"399_CR13","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1038\/jp.2008.50","volume":"28","author":"HL Halliday","year":"2008","unstructured":"Halliday HL. Surfactants: past, present and future. J Perinatol. 2008;28(Suppl 1):S47-56.","journal-title":"J Perinatol"},{"issue":"2","key":"399_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/jp.2011.125","volume":"33","author":"R Ramanathan","year":"2013","unstructured":"Ramanathan R, Bhatia JJ, Sekar K, et al. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. J Perinatol. 2013;33(2):119\u201325.","journal-title":"J Perinatol"},{"key":"399_CR15","unstructured":"Survanta\u00ae (beractant). Summary of product characteristics. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/6a704ce803670e6511a6c607e26ab87b557a3983. Accessed 17 May 2022."},{"key":"399_CR16","unstructured":"Infasurf\u00ae (calfactant). Prescribing information. https:\/\/infasurf.com\/prescribing-information\/. Accessed 20 June 2022."},{"issue":"3","key":"399_CR17","doi-asserted-by":"publisher","first-page":"e0230229","DOI":"10.1371\/journal.pone.0230229","volume":"15","author":"X Guo","year":"2020","unstructured":"Guo X, Luo S, Amidani D, et al. In vitro characterization and in vivo comparison of the pulmonary outcomes of poractant alfa and Calsurf in ventilated preterm rabbits. PLoS ONE. 2020;15(3):e0230229.","journal-title":"PLoS ONE"},{"key":"399_CR18","unstructured":"Curosurf\u00ae (poractant alfa). Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/21421. Accessed 9 May 2022."},{"key":"399_CR19","doi-asserted-by":"crossref","unstructured":"Singh N, Halliday HL, Stevens TP, et al. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2015;(12):CD010249.","DOI":"10.1002\/14651858.CD010249.pub2"},{"issue":"1","key":"399_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):39.","journal-title":"Syst Rev"},{"issue":"3","key":"399_CR21","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12\u20133.","journal-title":"ACP J Club"},{"key":"399_CR22","unstructured":"The IQVIA Institute. The Global Use of Medicines 2022: Outlook to 2026. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-global-use-of-medicines-2022. Accessed 11 November 2022."},{"issue":"7052","key":"399_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275\u201383.","journal-title":"BMJ"},{"issue":"1","key":"399_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1824-7288-40-40","volume":"40","author":"C Dani","year":"2014","unstructured":"Dani C, Ravasio R, Fioravanti L, et al. Analysis of the cost-effectiveness of surfactant treatment (Curosurf\u00ae) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment. Ital J Pediatr. 2014;40(1):40.","journal-title":"Ital J Pediatr"},{"key":"399_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/ejhpharm-2020-002465","volume":"29","author":"C Federici","year":"2022","unstructured":"Federici C, Fornaro G, Roehr CC. Cost-saving effect of early less invasive surfactant administration versus continuous positive airway pressure therapy alone for preterm infants with respiratory distress syndrome. Eur J Hosp Pharm. 2022;29(6):346\u201352.","journal-title":"Eur J Hosp Pharm."},{"key":"399_CR26","doi-asserted-by":"publisher","first-page":"S717","DOI":"10.1016\/j.jval.2020.08.1888","volume":"23","author":"M Solozabal","year":"2020","unstructured":"Solozabal M, L\u00f3pez-Sanrom\u00e0 M, P\u00e9rez I, et al. PRS8 budget IMPACT analysis of less invasive surfactant administration (LISA) technique as early rescue strategy for preterm infants with respiratory distress syndrome in Spain. Value Health. 2020;23:S717.","journal-title":"Value Health."},{"key":"399_CR27","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.1016\/j.jval.2018.09.2444","volume":"21","author":"R Yagudina","year":"2018","unstructured":"Yagudina R, Kulikov A, Serpik V. Prs50 - Cost-effectiveness analysis of surfactant therapy for the treatment of respiratory distress syndrome newborn in the Russian Federation. Value Health. 2018;21:S412.","journal-title":"Value Health."},{"issue":"7","key":"399_CR28","doi-asserted-by":"publisher","first-page":"A403","DOI":"10.1016\/j.jval.2016.09.324","volume":"19","author":"L Krasnova","year":"2016","unstructured":"Krasnova L, Vorobiev P, Tyurina I. Clinical and economic analysis of two surfactants for the prevention and treatment of respiratory distress syndrome. Value Health. 2016;19(7):A403.","journal-title":"Value Health."},{"issue":"3","key":"399_CR29","first-page":"3007","volume":"12","author":"G Yuan","year":"2019","unstructured":"Yuan G, Wu Z, Chen X, et al. Comparison of the efficacy and safety of bovine lung phospholipid and poractant alfa injections in the treatment of neonatal hyaline membrane disease with continuous positive airway pressure. Int J Clin Exp. 2019;12(3):3007\u201313.","journal-title":"Int J Clin Exp"},{"issue":"5","key":"399_CR30","first-page":"367","volume":"23","author":"S Brown","year":"2018","unstructured":"Brown S, Hurren J, Sartori H. Poractant alfa versus beractant for neonatal respiratory distress syndrome: a retrospective cost analysis. J Pediatr Pharmacol Ther. 2018;23(5):367\u201371.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"399_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ppul.23022","volume":"50","author":"A Kugelman","year":"2015","unstructured":"Kugelman A, Riskin A, Said W, et al. A randomized pilot study comparing heated humidified high-flow nasal cannulae with NIPPV for RDS. Pediatr Pulmonol. 2015;50(6):576\u201383.","journal-title":"Pediatr Pulmonol"},{"key":"399_CR32","unstructured":"Yao W, Jensen I, Claussen M, et al. Cost consequence analysis of using selective early surfactant administration vs. Standard surfactant administration via endotracheal intubation and mechanical ventilation. Presented at: annual meeting of the Pediatric Academic Societies (PAS); 30 April\u20134 May, 2021; Virtual. EP-152.10612021."},{"key":"399_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2022.105562","volume":"167","author":"FMS Arattu Thodika","year":"2022","unstructured":"Arattu Thodika FMS, Ambulkar H, Williams E, et al. Outcomes following less-invasive-surfactant-administration in the delivery-room. Early Hum Dev. 2022;167:105562.","journal-title":"Early Hum Dev"},{"key":"399_CR34","doi-asserted-by":"crossref","unstructured":"Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks\u2019 gestation. Pediatrics. 1999;103:e24.","DOI":"10.1542\/peds.103.2.e24"},{"key":"399_CR35","doi-asserted-by":"crossref","unstructured":"Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed. 2013;98:F122\u20136.","DOI":"10.1136\/archdischild-2011-301314"},{"key":"399_CR36","doi-asserted-by":"crossref","unstructured":"G\u00f6pel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open label, randomised, controlled trial. Lancet. 2011;378:1627\u201334.","DOI":"10.1016\/S0140-6736(11)60986-0"},{"key":"399_CR37","doi-asserted-by":"crossref","unstructured":"Isayama T, Iwami H, McDonald S, et al. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. JAMA. 2016;316:611\u201324.","DOI":"10.1001\/jama.2016.10708"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00399-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:50:04Z","timestamp":1683780604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00399-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00399-x","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"16 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Chiesi Farmaceutici S.p.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tiziana Magni, Natalia Meshchenkova, Martina Orlovic, Nicola Pelizzi and Chiara Ragni are employees of Chiesi Farmaceutici S.p.A.. Jyothsna Nathani, Lucia Perez-Kempner, Sheetal Sharma and Erika Turkstra were commissioned by Chiesi Farmaceutici S.p.A. and received a consulting fee to conduct the systematic review presented in the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TM, CR, NP, MO, NM (employees of Chiesi Farmaceutici S.p.A.), LP-K and ET contributed to the study conception and design; SS and JN contributed to the collection and assembly of data, data analysis, interpretation and preparation of the manuscript. All authors commented on the manuscript drafts and read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}